- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
Cell Line Development and Engineering
13 - 17 February 2012
|
2012 Cell Line Development and Engineering was a HUGE success. Following on from this positive response, we felt the need to share with you how the event went and some of the thoughts from both our speakers and delegates. Check out what happened at our 2012 event
2012 feedback from Europe's leading Cell Line Event
With the over-riding response of our recent 2012 Cell Line Development and Engineering being so positive, we felt the need to share with you how the event went and some of the thoughts from both our speakers and delegates. Check out what happended at our 2012 event:
Our exhibition room was a great opportunity for our sponsors and exhibitors to talk directly with our delegates, as well as our delegates to find out more about the latest technologies and services available to further develop and improve current cell lines.
One of the conference rooms at our 2012 event. Very representative of the constant full attendance throughout the 5 day.
One of the many interactive sessions organised to encourage the audience to get involved and make the most of the leading experts present.
With thanks to our 2012 spotlight sponsors
With thanks to our 2012 exhibitors
With thanks to our 2012 promotional participant
Media Partners
Latest tweets
2012 Feedback
''The organisers are to be complimented for putting together such a diverse, knowledgeable and friendly group of speakers''- Dr Daniel Adams, Executive Chairman, Global Head Business Development, Protein Sciences, USA
Other Events That Will Interest You
Non-Antibody Protein Production 2012
24 May 2012 - 25 May 2012
Diplomat Hotel, Prague, Czech Republic
Our extensive 2012 programme covered all topics essential to ensuring the most productive cell line and cost-effective strategies
Key topics included:
- Transient expression systems
- Optimising cell culture media
- Improved screening/Automation
- Clone selection technologies
- High throughput platforms
- Targeted integration and vector design
- Next-generation protein expression (incluign biosimilars and biobetters)
- The 'omics
- RNA technology
- Epigenetics and cell engineering
- Cell banking and viral contamination concerns
- Cell line quality and stability
Our 4 interactive seminars were a great success, covering both vital and newly emerging topics of concern in the cell line community
Our 4 sessions covered:
Optimising cell culture media
Alternative expresison systems
Introduction to the 'omics
Viral contamination: Understanding your cell culture
Reviews
"Well organised conference with broad spectrum of industrial cell culture topics"
"Useful overview of animal cell technology and its industrial applications"
"A human size meeting where it is easy to exchange views"
Other Events That Will Interest You
Bispecifics and Multivalent Antibodies
13 Jun 2012 - 14 Jun 2012
Hotel Palace Berlin, Berlin, Germany
Hear direct from our expert 2012 chairpersons on what was discussed at the 2012 event and the key topics to be discussed in 2013
With thanks to our Cell Line Development and Engineering 2012 Expert Academic and Biopharm Speaker Faculty
With thanks to our Cell Line Development and Engineering 2012 Expert Academic and Biopharm Speaker Faculty
Dr Richard Schwartz
Chief, Vaccine Production Program Lab
NIAID/NIH
|
Dr Trent Munro
Senior Research Officer
University of Queensland
|
Prof. Susan Sharfstein
Associate Professor of Nanobioscience
University at Albany
|
Manuel Carrondo
CEO
IBET, Portugal
|
Dr Regis Sodoyer, Head Platforms, R&D, Sanofi Pasteur, France
Dr Yves Durocher, Research Officer, National Research Council Canada, Canada
Dr Bernie Sweeney, Group Leader, Protein Expression and Purification, UCB Pharma, UK
Dr Athena Wong, Scientist, Genentech, USA
Dr Marcia Coyne, Senior Manager, Cell Banking & Testing Department, Genentech, USA
Dr Arifa S. Khan, Senior Investigator, CBER, FDA, USA
Dr Catherine Huntington, Scientist II, MedImmune, UK
Dr Sabine Geisse, Director / NLS, Novartis Pharma AG, Switzerland
Professor Torsten Tonn, Medical Director and CEO, German Red Cross Blood Donation Service East GmbH, Germany
Dr Jolanda Gerritsen, Manager, Cell Line Development, Genmab, The Netherlands
Dr Helen Lock, GSK, UK
Professor Alan Dickson, Director, Centre of Excellence in Biopharmaceutical, Faculty of Life Sciences, University of Manchester
Dr Daniel Adams, Executive Chairman, Global Head of Business Development, Protein Sciences, USA
Dr Glyn Stacey, Director, UK Stem Cell Bank, NIBSC, UK
Dr Matthias Hackl, Scientist, Vienna Institute of Biotechnology, Austria
Dr Yung-shyeng Tsao, Senior Principal Scientist, Merck, USA
Dr Alessia Bachmann, Molecular Biology Associate Scientist, Merck Serono, Italy
Dr Christina Andersen, Scientist, Symphogen A/S, Denmark
Dr Susanne Corisdeo, Research Scientist, Centocor, USA
Professor John Masters, Professor of Experimental Pathology, UCL, UK
Dr Markus Sock, Fraunhofer IME, Germany
Dr Thomas Jostock, Technology Platform leader, Integrated Biologics Profiling, Novartis, Switzerland
Dr Stéphane Olivier, Scientist/Project Manager, Protein Department, Vivalis, France
Dr Gudrun Schiedner, CSO, Cevec, Germany
Dr Thomas Schirrmann, Research Group Leader and Lecturer, Department of Biotechnology, Technische Universitaet Braunschweig, Germany
Dr Beate Kleuser, Head of Cell Biology, Biotech Process Sciences Department, Merck Serono, Switzerland
Dr Jörg von Hagen, Head, Process Development R&D, Merck KGaA, Germany
Dr Martin Powers, NICB, Dublin University, Ireland
Dr Padraig Doolan, Program Leader, Microarray/Bioinformatics core facility, NICB, Dublin City University, Ireland
Feeds | Like | Share    |
